Evidence map›Paper›PMID 37733154›Full record

Observational studyClinical and experimental medicine2023

Dipeptidyl-peptidase 3 and IL-6: potential biomarkers for diagnostics in COVID-19 and association with pulmonary infiltrates.

Stephan T Staudner, Simon B Leininger, Manuel J Vogel, Julian Mustroph, Ute Hubauer, Christine Meindl, Stefan Wallner, Petra Lehn, Ralph Burkhardt, Frank Hanses and 6 more

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in Clinical and experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Stephan T StaudnerDepartment of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany. stephan.staudner@gmail.com.
Simon B LeiningerDepartment of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Manuel J VogelDepartment of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Julian MustrophDepartment of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Ute HubauerDepartment of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Christine MeindlDepartment of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Stefan WallnerDepartment of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany.
Petra LehnDepartment of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany.
Ralph BurkhardtDepartment of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany.
Frank HansesEmergency Department, University Hospital Regensburg, Regensburg, Germany.
Markus ZimmermannEmergency Department, University Hospital Regensburg, Regensburg, Germany.
Gregor ScharfDepartment of Radiology, University Hospital Regensburg, Regensburg, Germany.
Okka W HamerDepartment of Radiology, University Hospital Regensburg, Regensburg, Germany.
Lars S MaierDepartment of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Julian Hupf *Emergency Department, University Hospital Regensburg, Regensburg, Germany.
Carsten G Jungbauer *Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
University Hospital Regensburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus SARS-CoV-2 spread worldwide, causing a respiratory disease known as COVID-19. The aim of the present study was to examine whether Dipeptidyl-peptidase 3 (DPP3) and the inflammatory biomarkers IL-6, CRP, and leucocytes are associated with COVID-19 and able to predict the severity of pulmonary infiltrates in COVID-19 patients versus non-COVID-19 patients. 114 COVID-19 patients and 35 patients with respiratory infections other than SARS-CoV-2 were included in our prospective observational study. Blood samples were collected at presentation to the emergency department. 102 COVID-19 patients and 28 non-COVID-19 patients received CT imaging (19 outpatients did not receive CT imaging). If CT imaging was available, artificial intelligence software (CT Pneumonia Analysis) was used to quantify pulmonary infiltrates. According to the median of infiltrate (14.45%), patients who obtained quantitative CT analysis were divided into two groups (> median: 55 COVID-19 and nine non-COVID-19, ≤ median: 47 COVID-19 and 19 non-COVID-19). DPP3 was significantly elevated in COVID-19 patients (median 20.85 ng/ml, 95% CI 18.34-24.40 ng/ml), as opposed to those without SARS-CoV-2 (median 13.80 ng/ml, 95% CI 11.30-17.65 ng/ml; p < 0.001, AUC = 0.72), opposite to IL-6, CRP (each p = n.s.) and leucocytes (p < 0.05, but lower levels in COVID-19 patients). Regarding binary logistic regression analysis, higher DPP3 concentrations (OR = 1.12, p < 0.001) and lower leucocytes counts (OR = 0.76, p < 0.001) were identified as significant and independent predictors of SARS-CoV-2 infection, as opposed to IL-6 and CRP (each p = n.s.). IL-6 was significantly increased in patients with infiltrate above the median compared to infiltrate below the median both in COVID-19 (p < 0.001, AUC = 0.78) and in non-COVID-19 (p < 0.05, AUC = 0.81). CRP, DPP3, and leucocytes were increased in COVID-19 patients with infiltrate above median (each p < 0.05, AUC: CRP 0.82, DPP3 0.70, leucocytes 0.67) compared to infiltrate below median, opposite to non-COVID-19 (each p = n.s.). Regarding multiple linear regression analysis in COVID-19, CRP, IL-6, and leucocytes (each p < 0.05) were associated with the degree of pulmonary infiltrates, as opposed to DPP3 (p = n.s.). DPP3 showed the potential to be a COVID-19-specific biomarker. IL-6 might serve as a prognostic marker to assess the extent of pulmonary infiltrates in respiratory patients.

Indexed as

COVID-19Artificial IntelligenceBiomarkersCOVID-19 TestingDipeptidyl-Peptidases and Tripeptidyl-PeptidasesHumansInterleukin-6SARS-CoV-2BiomarkersDipeptidyl-Peptidases and Tripeptidyl-PeptidasesDPP3 protein, humanIL6 protein, humanInterleukin-6Artificial intelligenceCOVID-19Dipeptidyl-peptidase 3IL-6Pulmonary infiltratesSARS-CoV-2

Identifiers

PMID37733154
PMCPMC10725357
OpenAlexW4386910892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.